All three of these studies showed significant increase in gastric residue rates on either capsule endoscopy after starting GLP-RAs (in the case of the study by Nakatani et al. [33]) or on gastric ultrasound in the GLP-1 user group compared to non-user groups (in the cases of the studies by Sherwin et al. and Sen et al. [35,36]); of note, all three studies reported significant residue rates in the non-GLP-1 RA user groups as high as 32.1 ± 24% and 32.1 ± 35.3% in the diabetic neuropathy and non-diabetic neuropathy groups, respectively, reported in the study by Nakatani et al. [33]. This evidence concerns the gene GLP1R and diabetic neuropathy.